P. A. Uber, H. J. Ross, A. O. Zuckermann, S. C. Sweet, P. A. Corris, K. McNeil, et al., “Generic Drug Immunosuppression in Thoracic Transplantation: An ISHLT Educational Advisory,” The Journal of Heart and Lung Transplantation, Vol. 28, No. 7, 2009, pp. 655-660. doi:10.1016/j.healun.2009.05.001

has been cited by the following article:

• TITLE: Short-Term Outcomes in Heart Transplant Recipients Treated with Generic Tacrolimus Compared to Prograf

  AUTHORS: Vinayak Dhungel, Monica M. Colvin-Adams, Peter M. Eckman

  KEYWORDS: Generic Tacrolimus; Heart Transplant

  JOURNAL NAME: Open Journal of Organ Transplant Surgery, Vol.3 No.2, May 15, 2013

  ABSTRACT: Calcineurin inhibitors are the cornerstone of solid organ transplant immunosuppression. Tacrolimus has only recently become available in a non-branded formulation, and there is little data on the efficacy and safety of generic tacrolimus, particularly following heart transplant. We performed a retrospective analysis of 21 consecutive patients who were treated with generic tacrolimus following heart transplant and compared rate of biopsy-proven acute cellular rejection to historical controls who were treated with Prograf. No significant difference in biopsy-proven acute cellular rejection was noted between the groups and rates of opportunistic infection and death were comparable. Although limited by the single-center, retrospective design, this preliminary data may be useful to clinicians facing the option of initiating generic tacrolimus following heart transplant.